Actively Recruiting
Phase 3 Study of Jitongning Tablets Compared to Placebo for Treating Active Ankylosing Spondylitis Evaluating Effectiveness and Safety in Adults Aged 18 to 65 with Kidney Yang Deficiency and Blood Stasis Syndrome
Led by Tasly Pharmaceutical Group Co., Ltd · Updated on 2024-11-21
408
Participants Needed
10
Research Sites
4 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the efficacy and safety of Jitongning tablets in adults with active axial spondyloarthritis ax-SpA. The study aims to determine if Jitongning tablets can improve symptoms and functions better than a placebo. It also assesses the safety of the tablets in this patient population. The trial is a randomized, double-blind, placebo-controlled Phase III study sponsored by Tasly Pharmaceutical Group Co., Ltd.
CONDITIONS
Brief Title
A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo
Research Team
W
Wei Liu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
